Handelsbanken Fonder AB Makes New Investment in Enliven Therapeutics, Inc. $ELVN

Handelsbanken Fonder AB acquired a new position in Enliven Therapeutics, Inc. (NASDAQ:ELVN) in the 2nd quarter, HoldingsChannel reports. The firm acquired 17,300 shares of the company’s stock, valued at approximately $878,000.

Other large investors also recently modified their holdings of the company. Vestal Point Capital LP boosted its position in shares of Enliven Therapeutics by 230.2% during the fourth quarter. Vestal Point Capital LP now owns 3,830,000 shares of the company’s stock valued at $58,982,000 after buying an additional 2,670,000 shares during the last quarter. Siren L.L.C. bought a new position in Enliven Therapeutics during the 1st quarter valued at $29,252,000. Affinity Asset Advisors LLC bought a new position in Enliven Therapeutics during the 1st quarter valued at $23,007,000. TCG Crossover Management LLC purchased a new position in Enliven Therapeutics during the 2nd quarter worth $9,990,000. Finally, Duquesne Family Office LLC grew its stake in shares of Enliven Therapeutics by 104.6% in the 3rd quarter. Duquesne Family Office LLC now owns 947,405 shares of the company’s stock worth $19,393,000 after acquiring an additional 484,405 shares in the last quarter. Institutional investors own 95.08% of the company’s stock.

Insiders Place Their Bets

In other news, CFO Benjamin Hohl sold 6,018 shares of the stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $58.58, for a total transaction of $352,534.44. Following the completion of the transaction, the chief financial officer directly owned 40,036 shares of the company’s stock, valued at $2,345,308.88. This represents a 13.07% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mika K. Derynck sold 158,795 shares of the firm’s stock in a transaction that occurred on Tuesday, August 4th. The stock was sold at an average price of $60.21, for a total transaction of $9,561,046.95. Following the sale, the director owned 87,373 shares of the company’s stock, valued at approximately $5,260,728.33. The trade was a 64.51% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 196,849 shares of company stock valued at $11,344,257. Company insiders own 3.00% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently commented on ELVN shares. Mizuho increased their target price on shares of Enliven Therapeutics from $62.00 to $73.00 and gave the company an “outperform” rating in a report on Tuesday. Weiss Ratings restated a “sell (d-)” rating on shares of Enliven Therapeutics in a report on Friday, July 17th. Guggenheim reduced their price objective on shares of Enliven Therapeutics from $80.00 to $78.00 and set a “buy” rating for the company in a research report on Thursday, August 6th. William Blair started coverage on shares of Enliven Therapeutics in a research note on Tuesday. They issued an “outperform” rating for the company. Finally, The Goldman Sachs Group boosted their target price on Enliven Therapeutics from $67.00 to $80.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Eight analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $75.00.

Enliven Therapeutics Price Performance

Shares of Enliven Therapeutics stock opened at $59.39 on Thursday. Enliven Therapeutics, Inc. has a 1 year low of $14.78 and a 1 year high of $62.32. The firm has a market cap of $4.35 billion, a PE ratio of -35.56 and a beta of 0.27. The stock has a fifty day moving average price of $52.34 and a 200-day moving average price of $41.61.

Enliven Therapeutics (NASDAQ:ELVN) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.10). As a group, equities analysts anticipate that Enliven Therapeutics, Inc. will post -1.67 EPS for the current fiscal year.

Enliven Therapeutics Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.